What's New for Vol. 2022, Supp. 11
Changes to patent and exclusivity information

Patents whose numbers are in italics have been extended under 35 USC 156. All expiration dates include applicable Sec. 156 and pediatric (PED) extensions.


Eylea (Injection) (Intravitreal) aflibercept
Drug Classes: Ophthalmic Agents:Ophthalmic Agents, Other
NDA Applicant: Regeneron Pharmaceuticals, Inc.      BLA No.: 125387  Prod. No.: 001 Rx (2MG/0.05ML); 002 Rx (2MG/0.05ML)
PatentsExpirationChange
Pat. No. D961376
Packaging
Pat. Sub. Date(s): None
Claim Types: Ornamental appearance of device or tablet
Aug 18, 2040New patent for this product
Pat. No. D961377
Packaging
Pat. Sub. Date(s): None
Claim Types: Ornamental appearance of device or tablet
Aug 18, 2040New patent for this product
Pat. No. 11433186
Devices and methods for precision dose delivery
Pat. Sub. Date(s): None
Claim Types: Device; Process
Aug 18, 2040New patent for this product
Pat. No. 11439758
Devices and methods for precision dose delivery
Pat. Sub. Date(s): None
Claim Types: Device
Aug 18, 2040New patent for this product
Pat. No. 11459373
Anti-VEGF protein compositions and methods for producing the same
Pat. Sub. Date(s): None
Claim Types: Process
Aug 18, 2040New patent for this product
Pat. No. 11459374
Anti-VEGF protein compositions and methods for producing the same
Pat. Sub. Date(s): None
Claim Types: Process
Aug 18, 2040New patent for this product
Pat. No. 11472861
Methods for producing aflibercept in chemically defined media having reduced aflibercept variants
Pat. Sub. Date(s): None
Claim Types: Process
Aug 18, 2040New patent for this product


Last edited: 8 December 2022
© 2001-2022 Bruce A. Pokras, All rights reserved worldwide